Goldman Sachs projects Pfizer’s 2025 EPS at $3.13, beating consensus of $2.89. Paxlovid sales expected to reach $4.3 billion vs. consensus of $3.7 billion; Vyndaqel forecast misses. Pfizer Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback